Under Rule 101 of India’s New Drugs and Clinical Trials Rules, 2019, the CDSCO can waive the requirement for a local Indian clinical trial if a new drug is already approved and marketed in a recognised country — the USA, UK, EU, Japan, Australia, or Canada — and fits a defined category. It is not automatic, and the clinical obligation does not disappear; it shifts to a post-approval Phase IV. But for the right asset, your FDA dossier may open the Indian market without a fresh Phase 3.
Most U.S. sponsors assume that entering India means running another trial. Sometimes it does not — and the sponsors who know when it does not save themselves months and a study they did not need to run.
What Rule 101 allows
Rule 101 gives the CDSCO the authority to waive a local clinical trial for a new drug already approved and marketed in a recognised regulatory jurisdiction, subject to conditions. The intent is sensible: if a drug has been studied and approved to a high standard elsewhere, and there is no reason to expect the Indian population to respond differently, requiring a duplicate local trial serves little purpose.
The categories that qualify
The waiver is not a blanket one. It applies to defined situations — for example, orphan drugs for rare diseases, certain gene and cell therapies, drugs for pandemic or special-defence use, and drugs that represent a significant therapeutic advance over the existing standard of care. The exact categories and conditions are set out in the rules and updated by the CDSCO over time, so the current text is what governs any specific asset.
The conditions attached
Even where a drug fits a category, the waiver carries conditions. Typically these include no major unexpected serious adverse events in the global program, no evidence of relevant pharmacokinetic or pharmacodynamic differences in the Indian population, and a written undertaking to conduct a Phase IV trial in India after approval.
That last point matters: the clinical obligation does not vanish. It moves downstream, from a pre-approval Phase 3 to a post-approval Phase IV. A sponsor planning around Rule 101 should budget for that commitment, not assume the trial requirement is gone entirely.
Why this is a strategy decision, not a paperwork one
The value of Rule 101 is realised before you build a protocol. If your asset qualifies, designing a fresh Indian Phase 3 you do not need is a costly detour. If it does not qualify, assuming it might and planning around a waiver that never comes is just as costly. The decision belongs at the front of your India strategy: assess the category fit and the conditions first, then design the pathway around the answer.
Frequently asked questions
Q: Can FDA approval waive an India clinical trial? A: Under Rule 101, the CDSCO can waive a local trial for a drug already approved in a recognised market and fitting a defined category — subject to conditions, and with the clinical obligation shifting to a post-approval Phase IV.
Q: Is the Rule 101 waiver automatic? A: No. It depends on the drug fitting a defined category, meeting safety and population conditions, and a written undertaking to conduct a Phase IV trial in India.
Q: What categories can qualify? A: Defined situations such as orphan drugs, certain gene and cell therapies, pandemic or special-defence drugs, and significant therapeutic advances — per the current text of the rules.
Wondering whether your asset qualifies for a Rule 101 waiver? Ask our India regulatory team before you plan a trial. → eteraflexconnects.com/services/india-licensing-partnership-advisory/
